Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 6/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | STK17B | O94768 | 1/20 | 0.30 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4724771 | 0.81 | CHRM4 (0.33) | GAACHRM4 | |
| SCHEMBL13663008 | 0.81 | GAA (0.42) | GAAMEN1NPC1RAB9AKMT2A | |
| SCHEMBL4300592 | 0.80 | GAA (0.41) | GAAMEN1NPC1RAB9AKMT2A | |
| SCHEMBL14594181 | 0.76 | GAA (0.73) | GAAMEN1NPC1RAB9AKMT2A | |
| SCHEMBL4302676 | 0.73 | MEN1 (0.48) | GAAMEN1NPC1RAB9AKMT2A | |
| SCHEMBL31093737 | 0.72 | ATR (0.44) | GAAMEN1NPC1RAB9AKMT2A | |
| SCHEMBL4299371 | 0.71 | GAA (0.47) | GAAMEN1NPC1RAB9AKMT2A | |
| SCHEMBL23169965 | 0.69 | ATR (0.46) | GAAMEN1NPC1RAB9AKMT2A | |
| SCHEMBL13663007 | 0.67 | KMT2A (0.39) | GAAMEN1NPC1RAB9AKMT2A | |
| SCHEMBL29813580 | 0.67 | ATR (0.42) | LCKATRMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270443-A1 | 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2006026760-A2 | 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270443-A1 | 1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS | IL2, IL4I1, IFNG | GAA 2007/4885MEN1 2721/4885NPC1 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.